Bmal1 knockdown suppresses wake and increases immobility without altering orexin A, corticotrophin-releasing hormone, or glutamate decarboxylase.

CONCLUSION: Bmal1 KD led to reduced activity, increased immobility, and dramatic reduction in time spent awake as well as an increase in sleep during the dark phase. Early after injection, there was a slight change in sleep but brain levels of orexin, CRH, and GAD remain unchanged. Control siRNA also affected sleep associated with changes in orexin levels. PMID: 29446232 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29446232?dopt=Abstract

Source: CNS Neuroscience and Therapeutics - February 14, 2018 Category: Neuroscience Authors: Akladious A, Azzam S, Hu Y, Feng P Tags: CNS Neurosci Ther Source Type: research